Indications |
Ophthalmic Ocular hypertension, Open-angle glaucoma Adult: 1 drop of 0.004% soln in the affected eye(s) once every evening. Renal impairment: Use with caution. Hepatic impairment: Use with caution. |
Contraindications |
Active intraocular inflammation. Pregnancy. |
Warnings / Precautions |
Aphakia or pseudophakia with torn posterior lens capsule; risk factors for cystoid macular oedema; history of intraocular inflammation; hepatic or renal impairment. Monitor for iris colour change. Contact lens to be removed before use and re-inserted 15 min after application. Lactation. |
Adverse Reactions |
Increase in brown pigmentation of iris and periorbital tissue; ocular hyperaemia; decreased visual acuity; foreign body sensation; blepharitis; ocular irritation and pain; darkening, thickening and lengthening of eyelashes; macular oedema. |
Mechanism of Actions |
Travoprost, a prodrug and synthetic analogue of dinoprost (prostaglandin F2α), reduces intraocular pressure by increasing uveoscleral outflow of aqueous humour. Onset: 2 hr. Duration: At least 24 hr. Absorption: Absorbed through cornea after ocular instillation. Peak plasma concentration of travoprost free acid in 30 min. Metabolism: Hydrolysed by esterases in the cornea to its biologically active free acid. Metabolised to inactive metabolites systemically. Mean terminal elimination half-life of travoprost free acid: 45 min. Excretion: Excreted in urine (<2% as active metabolite). |
Storage Conditions |
Ophthalmic: Store at 2-25°C (36-77°F). |
ATC Classification |
S01EE04 - travoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma. |
Storage |
Ophthalmic: Store at 2-25°C (36-77°F). |
Available As |
|
Travoprost
Post Review about Travoprost Click here to cancel reply.
Travoprost Containing Brands
Travoprost is used in following diseases
Drug - Drug Interactions of Travoprost
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.